MetricSide LogoMetricSide
Learn
  1. Home
  2. Companies
  3. Healthcare
  4. AIRS
OverviewMetricsPricesRevenue & ProfitAssets & LiabilitiesCash FlowMarginsPrice RatiosOthers
MetricSide

Standardized stock fundamentals and valuation metrics. Analyze revenue, EBITDA, free cash flow, and more with interactive charts.

Stock Sectors

  • Technology
  • Healthcare
  • Financials
  • Consumer
  • Industrials
  • Energy
  • Real Estate
  • Materials

Legal & Contact

  • Terms of Service
  • Privacy Policy
  • Contact Us
Not Financial Advice: MetricSide is a data aggregation and visualization tool. Nothing on this website constitutes investment advice, a recommendation, or a solicitation to buy or sell any security. All data is provided for informational and educational purposes only. Past performance is not indicative of future results. Always consult a qualified financial professional before making investment decisions. Data accuracy is not guaranteed — verify critical information against official sources.

© 2026 MetricSide. All rights reserved.

AirSculpt Technologies (AIRS) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

AirSculpt Technologies
NasdaqGM•Healthcare•Medical Care Facilities
$2.24+0.13(0.06%)Market open
Market Cap
$163.52M
P/S
1.1x
P/B
1.6x

AirSculpt Technologies, Inc., together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States and Canada. The company offers AirSculpt, a body contouring treatment that removes fat and tightens skin while sculpting targeted areas of the body in a minimally invasive procedure. It also provides AirSculpt+, a procedure that permanently removes fat and tightens the skin with unparalleled precision and finesse; and AirSculpt Smooth, an advanced cellulite removal tool. In addition, it provides fat removal procedures across treatment areas, such as the stomach, back, and buttocks; and fat transfer procedures that transfers the patient's own fat cells to enhance the buttocks, breasts, hips, aging hands, or other areas. Further, the company's body contouring procedures include the Power BBL, a Brazilian butt lift procedure; the Up a Cup, a breast enhancement procedure; and the Hip Flip, an hourglass contouring procedure. Additionally, it operates various centers. The company was founded in 2012 and is headquartered in Tampa, Florida.

D

How this company scores

WeakMetricSide Score: 47/100

Grade capped at D — Interest coverage below 1× (-3.0x) — earnings cannot cover interest. Strongest: Profitability (15/25); weakest: Growth (6/25).

Profitability15/25
Growth6/25
Balance Sheet & Red Flags15/25
Cash & Earnings Quality11/25
Strengths
Low leverageProfit converts from growthImproving leverageImproving margins
Grade capped at D
  • Interest coverage below 1× (-3.0x) — earnings cannot cover interest.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 220.3x5y range 32.9x – 220.3x
P/E 220.3x
P/S · 1.1x5y range 0.8x – 3.0x
P/S 1.1x · below its 17-quarter median

Currently below its 17-quarter median.

P/B · 1.6x5y range 1.4x – 12.0x
P/B 1.6x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 6 of the last 8 quarters — earnings are not translating to cash.

Price & Volume
Market Cap $163.52M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue
$150.72M
9%
Q. Revenue
$42.90M
2Q
TTM EBITDA
$-333,000
2Q
TTM Op. Income
$-12.59M
2Q
Q. Op. Income
$-29,000
104%
TTM Net Income
$-11.74M
19%
Q. Net Income
$-1.11M
88%
EPS
$-0.02
100%
Shares Out.
$70.79M
2Q
$150.72M in TTM revenue declined 8.7% YoY, reaching $42.90M last quarter. TTM EBITDA of $-333,000 and TTM operating income of $-12.59M show growth is flowing through to the bottom line. However, net income is negative at $11.74M — growth is not yet reaching the bottom line. Over the past year, TTM revenue is down 9% — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin
6.8%
26%
Op. Margin
-0.1%
104%
Net Margin
-2.6%
93%
Op. margin of -0.1% is down 1.9% YoY — costs are rising relative to revenue. Net margin at -2.6% Over the past year, operating margin is down 104% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio
N/A
P/S Ratio
1.1x
38%
P/B Ratio
1.6x
51%
P/S of 1.1x and P/B of 1.6x. P/S is low relative to typical market levels.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets
$193.28M
3Q
Cash
$18.82M
3Q
Long-Term Debt
$33.11M
7Q
Book Value
$104.83M
3Q
D/E Ratio
0.3
3Q
Debt/EBITDA
11.4
71%
With $193.28M in assets and $33.11M in long-term debt, D/E is 0.3and book value is $104.83M — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has fallen for 3 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow
$-1.24M
125%
TTM Free Cash Flow
$760,000
484%
FCF Margin
0.5%
520%
FCF / Net Income
-0.1
575%
TTM FCF of $760,000 on $-1.24M in operating cash flow. The FCF / Net Income ratio of -0.1x means the business consumes cash — it is not yet self-funding. Over the past year, free cash flow is up 484% — a weakening trend.

Related Stocks in Healthcare

View Sector
LLY$938.28B
Lilly (Eli)
Drug Manufacturers - General
JNJ$586.47B
Johnson & Johnson
Drug Manufacturers - General
ABBV$411.57B
AbbVie
Drug Manufacturers - General
MRK$303.29B
Merck & Co.
Drug Manufacturers - General
UNH$249.74B
UnitedHealth Group
Healthcare Plans
TMO$203.77B
Thermo Fisher Scientific
Diagnostics & Research
AMGN$201.34B
Amgen
Drug Manufacturers - General
GILD$191.61B
Gilead Sciences
Drug Manufacturers - General
· below its 19-quarter median

Currently below its 19-quarter median.

Revenue Decline

Red Flag

TTM revenue has contracted 13.4% — significant decline indicating deteriorating demand.

Cash Burn

Watch

6 of the last 8 quarters had negative FCF — inconsistent cash generation raises sustainability concerns.

Share Dilution

Red Flag

Shares outstanding increased 22.8% — significant dilution, likely from stock compensation or capital raises.